Nasdaq gnlx.

WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ...May 15, 2023 · Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ... Jan 26, 2023 · Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ... Home GNLX • NASDAQ. add. Share. Genelux Corp. $13.33. After Hours: $13.33. (0.00 ... History Says the Nasdaq Could Soar in 2024 -- 5 Stocks You'll Wish You'd ...

Genelux ( NASDAQ: GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...

WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...Web

Genelux press release (NASDAQ:GNLX): Q2 GAAP EPS of -$0.23.; At June 30, 2023, the company had cash on hand in the amount of $27.1 million. Net loss was $5.8 million for the second quarter of 2023 ...In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebGenelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial in resistant/refractory ...Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ...Explore new charts. Discover historical prices for GNLX stock on Yahoo Finance. View daily, weekly or monthly format back to when Genelux Corporation stock was issued.

Genelux Corp (NASDAQ: GNLX) has experienced a rise in its stock price by 11.85 compared to its previous closing price of 10.46. However, the company has seen a gain of 12.72% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-07 that WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) — Genelux […]

Aug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...

4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ...About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Bed Bath & Beyond Inc. Common Stock. 1.74%. 12.06.2023 г. ... 103426 GNLX GENELUX CORP NASDAQ Capital 6.00 2,500,000 1/26/2023 $15,000,000 Priced 3 1241592-105143 QSG QuantaSing Group Ltd NASDAQ Global ...Genelux Corporation (NASDAQ:GNLX) rose 18.4% to $23.99. Shengfeng Development Limited (NASDAQ:SFWL) gained 17.2% to $6.09. Dunxin Financial Holdings Limited (NYSE:DXF) climbed 16.8% to $1.73.Oct 13, 2023 · Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of. Mar 23, 2023 · Genelux Corporation. WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical ... GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...

Based on analysts offering 12 month price targets for GNLX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your ...Genelux Corp. GNLX (U.S.: Nasdaq). REAL TIME 3:03 PM EST 11/30/23. $11.81USD ... GNLX. Significant News Only. No significant news for GNLX in the past two years ...Genelux Corporation (NASDAQ:GNLX) rose 18.4% to $23.99. Shengfeng Development Limited (NASDAQ:SFWL) gained 17.2% to $6.09. Dunxin Financial Holdings Limited (NYSE:DXF) climbed 16.8% to $1.73.Genelux Corp (NASDAQ:GNLX) Benchmark initiated coverage on Genelux with a Speculative Buy rating and announced a price target of $10. The company’s stock has a 52-week high of $13.28 .Find the latest news headlines from Genelux Corporation Common Stock (GNLX) at Nasdaq.com.The latest price target for . Genelux (NASDAQ: GNLX) was reported by Maxim Group on September 12, 2023.The analyst firm set a price target for $40.00 expecting GNLX to rise to within 12 months (a ...

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...

Genelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial in resistant/refractory ...Genelux Corporation Common Stock (GNLX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.View real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: …The latest price target for . Genelux (NASDAQ: GNLX) was reported by Maxim Group on September 12, 2023.The analyst firm set a price target for $40.00 expecting GNLX to rise to within 12 months (a ...Uncover the latest insider trading activity for Genelux Corporation (GNLX). Know which insiders are buying and selling along with top shareholders and ownership breakdown. Dashboard Markets Discover Watchlist Portfolios Screener. Genelux Corporation. NasdaqCM:GNLX Stock Report. Mkt Cap: US$317.1m. Add to watchlist.Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX...Le titre Ampio Pharmaceuticals (AMEX: AMPE) a chuté vendredi de 45,05% à 3,17 dollars lors de la session ordinaire. L’action Intelligent Bio Solutions (NASDAQ: …WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...Web

Genelux | 726 followers on LinkedIn. Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of …

WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...

We explain how to buy Genelux Corporation Common Stock stock, compare the best stock trading platforms and use a detailed analysis to learn about (GNLX).As of this writing, Genelux Corp (NASDAQ:GNLX) shares are trading at above $22.30 with a 52-week range of $5.35 to $39.27, giving the company a market capitalization of more than $527 million. 2 ...According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history.CIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ...WebA high-level overview of Genelux Corporation (GNLX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.See the latest Genelux Corp stock price (GNLX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.GNLX. --Genelux Corporation, a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share ...Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WebWESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...WebGenelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials... Instagram:https://instagram. yyy etfpnc bank stocksnew rtx cardswatchlist share market Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact. Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients. LEARN MORE. half dollar kennedy 1964 valueewq stock Late clinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) announced a private placement of 1.67M shares at a price of $20 per share, for gross proceeds of approximately $33M.Proceeds from ... healthcare penny stocks Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. GNLX U.S.: Nasdaq Genelux Corp. Watch list Set a price target alert After Hours Last Updated: Oct 10, 2023 6:54 p.m. EDT Delayed quote $ 23.00 0.97 4.40% After Hours Volume: 3.98K Advanced...WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ...Web